Selective serotonin reuptake inhibitors and withdrawal symptoms: A review of the literature

Human Psychopharmacology

Volumn 12, Issue 4, 1997, Pages 309-323

  Therrien, François ^a   Markowitz, John S ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Fluoxetine; Fluvoxamine; Paroxetine; Serotonin; Withdrawal symptoms

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOM; WITHDRAWAL SYNDROME;

EID: 0030849295     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199707/08)12:4<309::AID-HUP855>3.0.CO;2-A     Document Type: Review

References (61)

1. Andersen, H. and Kristiansen, E. S. (1959). Tofranil treatment of endogenous depressions. Acta Psychiatrica Scandinavica, 34, 387-397.
2. Akaoka, H. and Aston-Jones, G. (1993). Indirect serotonergic agonists attenuate neuronal opiate withdrawal. Neuroscience, 54, 561-565.
3. Barr, L. C., Goodman, W. K. and Price, L. H. (1994). Physical symptoms associated with paroxetine discontinuation. American Journal of Psychiatry, 151, 289.
4. Berlin, C. S. (1996). Fluoxetine withdrawal symptoms. Journal of Clinical Psychiatry, 57, 93-94.
5. Bialos, D., Giller, E., Jatlow, P., Docherty, J. and Harkness, L. (1982). Recurrence of depression after discontinuation of amitriptyline. American Journal of Psychiatry, 139, 325-329.
6. Black, D. W., Wesner, R. and Gabel, J. (1993). The abrupt discontinuation of fluvoxamine in patients with panic disorder. Journal of Clinical Psychiatry, 54, 146-149.
7. Bloch, M., Stager, S. V., Braun, A. R. and Rubinow, D. R. (1995). Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet, 346, 57.
8. Bouchard, R. H., Pourcher, E. and Vincent, P. (1989). Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry, 146, 1352-1353.
9. Brod, T. M. (1989). Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry, 146, 1353.
10. Choo, V. (1993). Paroxetine and extrapyramidal reactions. Lancet, 341, 624.
11. Christensen, R. C. (1995). Adverse interaction of paroxetine and cyproheptadine. Journal of Clinical Psychiatry, 56, 433-434.
12. Cooper, G. L. (1988). The safety of fluoxetine - an update. British Journal of Psychiatry, 153 (Suppl. 3), 77-86.
13. Debattista, C. and Schatzberg, A. F. (1995). Physical symptoms associated with paroxetine withdrawal. American Journal of Psychiatry, 152, 1235-1236.
14. DeVane, C. L. (1994). Pharmacokinetics of the newer antidepressants: clinical relevance. American Journal of Medicine, 97 (Suppl.), 6S-13S.
15. Diamond, B. I., Borison, R. L., Katz, R. and DeVeaugh-Greiss, J. (1989). Rebound reactions due to clomipramine. Psychopharmacology Bulletin, 25, 209-212.
16. Dilsaver, S. C. (1994). Withdrawal phenomena associated with antidepressants and antipsychotics. Drug Safety, 10, 103-114.
17. Dominguez, R. A. and Goodnick, P. J. (1995). Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy, 15, 778-780.
18. Dubovsky, S. L. and Thomas, M. (1995). Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Journal of Psychosomatic Research, 39, 429-444.
19. Einbinder, E. (1995). Fluoxetine withdrawal? American Journal of Psychiatry, 152, 1235.
20. Ellison, J. M. (1994). SSRI withdrawal buzz. Journal of Clinical Psychiatry, 55, 544-545.
21. Farah, A. and Lauer, T. E. (1996). Possible venlafaxine withdrawal syndrome. American Journal of Psychiatry, 153, 576.
22. Fava, G. and Grandi, S. (1995). Withdrawal syndromes after paroxetine and sertraline discontinuation. Journal of Clinical Psychopharmacology, 15, 374-375.
23. Feder, R. (1991). Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Journal of Clinical Psychiatry, 52, 163-164.
24. Finley, P. R. (1994). Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions. Annals of Pharmacotherapy, 28, 1359-1369.
25. Frommer, D. A., Kulig, K. W., Marx, J. A. and Rumack, B. (1987). Tricyclic antidepressant overdose. Journal of the American Medical Association, 257, 521-526.
26. Frost, L. and Lal, S. (1995). Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. American Journal of Psychiatry, 152, 810.
27. Geller, B., Cooper, T. B. and Carr, L. G. (1987). Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. Journal of Clinical Psychopharmacology, 7, 252-254.
28. Glassam, A. H. and Preud'homme, X. A. (1993). Review of the cardiovascular effects of heterocyclic antidepressants. Journal of Clinical Psychiatry, 54 (Suppl. 2), 16-22.
29. Goldbloom, D. S. and Kennedy, S. H. (1991). The interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Journal of Clinical Psychiatry, 52, 261-262.
30. Heninger, G. R., Delgado, P. L. and Charney, D. S. (1996). The revised theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry, 29, 2-11.
31. Hyman, S. E. and Nestler, E. J. (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153, 151-162.
32. Kasantikul, D. (1995). Reversible delirium after discontinuation of fluoxetine. Journal of the Medical Association of Thailand, 78, 53-54.
33. Katz, R. J. and Rosenthal, M. (1994). Adverse interaction of cyproheptadine with serotonergic antidepressants. Journal of Clinical Psychiatry, 55, 314-315.
34. Keuthen, N. J., Cyr, P., Ricciardi, J. A., Minichiello, W. E., Buttolph, M. L. and Jenike, M. A. (1994). Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. Journal of Clinical Psychopharmacology, 14, 206-207.
35. Kramer, J. C., Klein, D. F. and Fink, M. (1961). Withdrawal symptoms following discontinuation of imipramine therapy. American Journal of Psychiatry, 118, 549-550.
36. Kreider, M. S., Bushnell, W. D., Oakes, R. and Wheadon, D. E. (1995). A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Journal of Clinical Psychiatry, 56, 142-145.
37. Law, W., Petti, T. A. and Kazdin, A. (1981). Withdrawal symptoms after graduated cessation of imipramine in children. American Journal of Psychiatry, 138, 647-650.
38. Leiter, F. L., Nierenberg, A. A., Sanders, K. M. and Stern, T. A. (1995). Discontinuation reactions following sertraline. Biological Psychiatry, 38, 694-695.
39. Lejoyeux, M., Ades, J., Mourad, I., Solomon, J. and Dilsaver, S. C. (1996). Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs, 5, 278-292.
40. Levy, A. D. and Van de Kar, L. D. (1992). Endocrine and receptor pharmacology of serotonergic anziolytics, antipsychotics and antidepressants. Life Sciences, 51, 83-94.
41. Linnoila, V. M. and Virkkunen, M. (1992). Aggression, suicidality, and serotonin. Journal of Clinical Psychiatry, 53 (Suppl. 6), 46-51.
42. Lipinski, J. F., Mallya, G., Zimmerman, P. and Pope, H. G. (1989). Fluoxetine-induced akathisia: clinical and theoretical implications. Journal of Clinical Psychiatry, 50, 339-342.
43. Louie, A. K., Lannon, R. A. and Ajari, L. J. (1994). Withdrawal reaction after sertraline discontinuation. American Journal of Psychiatry, 151, 450-451.
44. Mallya, G., White, K. and Gunderson, C. (1993). Is there a serotonergic withdrawal syndrome? Biological Psychiatry, 33, 851-852.
45. Marriott, S. and Tyrer, P. (1993). Benzodiazepine dependence: avoidance and withdrawal. Drug Safety, 9, 93-103.
46. Nemeroff, C. B., DeVane, C. L. and Pollock, B. G. (1996). Antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153, 311-320.
47. Pacheco, L., Malo, P., Aragues, E. and Etxebeste, M. (1996). More cases of paroxetine withdrawal syndrome. British Journal of Psychiatry, 169, 384.
48. Phillips, S. D. (1995). A possible paroxetine withdrawal syndrome. American Journal of Psychiatry, 152, 645-646.
49. Pyke, R. E. (1995). Paroxetine withdrawal syndrome. American Journal of Psychiatry, 152, 149-150.
50. Rafieian-Kopaei, M., Gray, A. M., Spencer, P. S. J. and Sewell, R. D. E. (1995). Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning. European Journal of Pharmacology, 275, 185-189.
51. Richelson, E. (1994). The pharmacology of antidepressants at the synapse: Focus on the newer compounds. Journal of Clinical Psychiatry, 55 (Suppl. 5), 34-39.
52. Rosenblatt, J. E. (1994). Toxicology and drug interactions: two more cases of fluoxetine withdrawal (and SSRI withdrawal symptoms online). Currents in Affective Illness, 13, 15-17.
53. Rosenstock, H. A. (1996). Sertraline withdrawal in two brothers: a case report. International Clinical Psychopharmacology, 11, 58-59.
54. Sanders-Bush, E., Breeding, M., Knoth, K. and Tsutsumi, M. (1989). Sertraline-induced desensitization of the serotonin 5-HT2 receptor transmembrane signaling system. Psychopharmacology, 99, 64-69.
55. 3H]3-PPP binding to σ sites in rat brain. European Journal of Pharmacology, 165, 335-336.
56. Stanford, S. C. (1996). Prozac: panacea or puzzle? Trends in Pharmaceutical Sciences, 17, 150-154.
57. Stoukides, J. A. and Stoukides, C. A. (1991). Extrapyramidal symptoms upon discontinuation of fluoxetine. American Journal of Psychiatry, 148, 1263.
58. Szabadi, E. (1992). Fluvoxamine withdrawal syndrome. British Journal of Psychiatry, 160, 283-284.
59. Thomas, D. R., Nelson, D. R. and Johnson, A. M. (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
60. Tulloch, I. F. and Johnson, A. M. (1992). The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. Journal of Clinical Psychiatry, 53 (Suppl. 1), 7-12.
61. Tyrer, P. (1984). Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. Journal of Affective Disorders, 6, 1-7.